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At a glance commentary 
Scientific knowledge on the subject 
Exacerbations are thought to be key events in the natural history of bronchiectasis. No 
previous studies have identified the predictors of future bronchiectasis exacerbations. In 
contrast to other respiratory disorders such as COPD, a “frequent exacerbator phenotype” has 
not been described in bronchiectasis. A clinically relevant phenotype should be stable over 
time, and be associated with clinically relevant outcomes. This study of more than 2000 
bronchiectasis patients from 10 clinical centres across Europe and Israel examined the 
temporal stability and clinical outcomes of frequently exacerbating patients with 
bronchiectasis. 
What this study adds to the field  
We demonstrate that a prior history of exacerbations is the strongest predictor of future 
exacerbations over 3 years follow-up. The “frequent exacerbator phenotype” was relatively 
stable over time and was consistently identified in all 10 centres. Patients with frequent 
exacerbations, particularly those experiencing 3 or more exacerbations per year, had worse 
quality of life, more frequent hospitalizations and increased mortality over 5 years after 
adjustment for relevant confounders. These data demonstrate the critical importance of 
exacerbations the natural history of bronchiectasis and emphasise the importance of 
exacerbation prevention in clinical management.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract: 
Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical 
predictors and outcomes of frequently exacerbating patients are not well described.  
Objectives: To establish if there is a “frequent exacerbator phenotype” in bronchiectasis and 
the impact of exacerbations on long-term clinical outcomes.  
Methods: 
We studied bronchiectasis patients enrolled from 10 clinical centres in Europe and Israel, with 
up to 5-years follow-up. Patients were categorized by baseline exacerbation frequency (0, 1, 2 
or >3 per year). The repeatability of exacerbation status was assessed as well as the 
independent impact of exacerbation history on hospitalizations, quality of life and mortality.  
Measurements and Main Results: 
2572 patients were included. Frequent exacerbations were the strongest predictor of future 
exacerbation frequency suggesting a consistent “phenotype”. The incident rate ratios for 
future exacerbations were 1.73 (95%CI 1.47-2.02, p<0.0001) for 1 exacerbation per year, 3.14 
(95%CI 2.70-3.66, p<0.0001) for 2 exacerbations and 5.97 (95%CI 5.27-6.78, p<0.0001) for 
patients with >3 exacerbations per year at baseline.  
Additional independent predictors of future exacerbation frequency were Haemophilus 
influenzae and Pseudomonas aeruginosa infection, forced expiratory volume in 1 second, 
radiological severity of disease and co-existing COPD. Frequently exacerbating patients had 
worse quality of life and were more likely to be hospitalized during follow-up. Mortality over 
up to 5 years follow-up increased with increasing exacerbation frequency.  
Conclusions: The frequent exacerbator phenotype in bronchiectasis is consistent over time and 
shows high disease severity, poor quality of life and increased mortality during follow-up. 
 Keywords: exacerbations, bronchiectasis, antibiotics, infection, mortality 
 
  
Background: 
Bronchiectasis is a clinical syndrome defined by abnormal, usually permanent dilatation of the 
bronchi associated with cough and sputum production.(1) In addition, for many patients the 
daily symptoms of the disease are accompanied by unpredictable worsening of symptoms 
greater than the normal day to day variation and referred to as exacerbations.(2,3)  
Exacerbations are recognised as important events in the natural history of bronchiectasis. 
International guidelines for bronchiectasis recommend treatment with, for example, inhaled or 
oral prophylactic antibiotic therapy for patients with 3 or more exacerbations per year with the 
aim of preventing exacerbations.(4-6) Exacerbations form part of the Bronchiectasis Severity 
Index (BSI), a multidimensional severity assessment tool for bronchiectasis.(7) In addition, 
exacerbation frequency or the time to first exacerbation have been the primary end-point for 
the majority of phase 3 randomized clinical trials in bronchiectasis.(8-11) 
It is surprising, therefore, that there have been few published studies describing the frequency 
of exacerbations over time and risk factors for exacerbations in bronchiectasis. Bronchiectasis 
is a highly heterogeneous disease in terms of aetiology, severity and clinical outcomes.(1-7) 
Exacerbation frequency is no different and patient characteristics vary, with reported 
frequency of exacerbations across different populations ranging from 0 to 9 events per patient 
per year.(1)  
In clinical practice, it is important to identify patients who are at risk of future exacerbations in 
order to target preventative therapies appropriately. For research, it is important to identify 
patients likely to have future exacerbations in order to adequately power clinical trials.(7-11) 
In COPD, Hurst et al, identified a frequent exacerbator “phenotype” by demonstrating that 
over a 3 year period, exacerbation frequency showed a relative degree of stability.(12) An 
accepted definition of phenotypes for COPD originally proposed by Han et al requires “a single 
or combination of disease attributes that describe differences between individuals with COPD 
as they relate to clinically meaningful outcomes (symptoms, exacerbations, response to 
therapy, rate of disease progression, or death)”.(13) This definition can also be applied to 
patients with bronchiectasis.(13,14) Thus to be a valid patient phenotype in bronchiectasis, the 
“frequent exacerbator” should show stability over time and should be linked to clinically 
meaningful outcomes such as quality of life (QoL), future exacerbations, disease progression 
and/or death.  
In this study, we used a European patient cohort to determine whether frequent exacerbator 
status was stable over time and to determine its relationship with clinical outcomes. Some of 
the results of this study have previously been reported as an abstract.(15)      
 
 
Methods: 
We analysed data from bronchiectasis patients enrolled in 10 different bronchiectasis clinical 
centres across Europe (including Israel as an EU affiliated country) (Dundee, Edinburgh, 
Newcastle – United Kingdom; Haifa - Israel; Galway - Ireland; Leuven - Belgium; Athens - 
Greece; Monza - Italy; Barcelona - Spain; Vojvodina - Serbia) between 2007 and 2013. Details 
of this cohort has been described previously.(16,17) Inclusion criteria were : Consecutive 
patients aged ≥18 years; diagnosis of bronchiectasis made by a specialist physician; high-
resolution computed tomographic scan (HRCT); a clinical history consistent with 
bronchiectasis. Exclusion criteria were: Cystic fibrosis, traction bronchiectasis due to 
pulmonary fibrosis and active non-tuberculous mycobacterial disease. 
Local ethics committee or institutional review board, approved the data collection at each site. 
Diagnostic work-up and assessment was made following the 2010 British Thoracic Society 
(BTS) guidelines. (6) 
Baseline data collection was performed when patients were clinically stable and free from 
antibiotic therapy for exacerbations for a minimum of 4 weeks. Chronic infection was defined 
by isolation of the same pathogen in two or more cultures, at least 3 months apart in a 12-
month span, with the patient in stable state (18). A core dataset consisting of demographics, 
previous medical history, comorbidities, as well as radiological, laboratory and microbiological 
findings was recorded at each site. QoL was measured by the St Georges Respiratory 
Questionnaire (SGRQ) and severity of disease was evaluated by the Bronchiectasis Severity 
Index (BSI). (7)  Prophylactic antibiotic therapy at baseline was defined as administration of 
antibiotics with prophylactic intention, rather than for treatment of an exacerbation, for at 
least 28 days prior to baseline. 
For the purposes of analysis, 3 or more exacerbations per year were regarded as frequent 
exacerbations based on the ERS bronchiectasis guidelines (4) and patients were subdivided by 
a history of 0, 1, 2 or 3 or more exacerbations per year for analysis. 
 
Outcomes 
Outcomes were evaluated for up to 5 years of follow-up. Outcomes were: all cause mortality; 
exacerbations: defined as as the requirement for antibiotics in the presence of one or more 
symptoms of increasing cough, increasing sputum volume, worsening sputum purulence, 
worsening dyspnoea, increased fatigue/malaise, fever, and haemoptysis; and severe 
exacerbations: defined according to BTS guidelines as unscheduled hospitalisations or 
emergency department visits for exacerbations or complications as recorded from patient 
histories and verified using administrative databases.(6) 
Exacerbations were recorded for 12 months after the first visit in all patients and for 3 years in 
a subset.  
 Statistical analysis 
Descriptive statistics of median with 25-75% interquartile range (IQR) were used for 
continuous data, and absolute frequencies and percentages for categorical data. Subgroup 
comparisons were performed using the Mann-Witney U-Test or Chi-squared test, depending 
on data type. A comparison-wise significance level of 5% was used. 
To determine independent predictors of future exacerbation frequency we used a negative 
bionomial model with adjustment for length of follow-up time. Results are reported as incident 
rate ratios (IRR) with 95% confidence intervals (95% CI). For multivariable mortality analysis, a 
multivariable Cox regression analysis was used. The proportional hazards assumption was 
checked by inspection of log minus log plots. Variables included in the model were those 
determined to be clinically significant in impacting on mortality. Multivariable analysis of 
binary outcomes was performed using multivariable logistic regression.  The accuracy of prior 
exacerbations to predict future exacerbations was reported using sensitivity and specificity and 
associated likelihood ratios. Discrimination was assessed by the area under the receiver 
operator characteristic curve (ROC). A multiple linear regression model was applied to 
determine the variables with independent impact on QoL.  All analyses were performed using 
SPSS version 21 (SPSS, Chicago, IL, USA) for Windows and Graph Pad Prism Version 5 (Graph 
Pad Software, Inc. San Diego, CA, USA).  
 
 
 
 
 
Results: 
Patient characteristics:  
The study population was composed of 2596 patients. The median age was 67 years 
(interquartile range (IQR) 57-74), 38.9% were male and 61.9% of patients were never smokers. 
Further patient characteristics are shown in table 1. The aetiologies of bronchiectasis were 
typical of European cohorts, with most patients classified as idiopathic (42%), with post-
infective aetiology (17%), COPD (9%), asthma (6%), connective tissue diseases (6%) and allergic 
bronchopulmonary aspergillosis (5%) also being common underlying causes.  
The patient disposition in the study is shown in figure 1. The median exacerbation frequency 
prior to the study baseline was 2 per year. Exacerbation history was not recorded in 24 
subjects. In the remaining 2572 patients, 657 (25.3%) patients had 0 exacerbations, 452 
(17.4%) had 1 exacerbation, 497 (19.1%) had 2 exacerbations and 966 (37.2%) patients had 3 
or more exacerbations. 25.9% of patients had at least one hospital admission for a severe 
exacerbation prior to the study. 
Table 1 shows the characteristics of patients according to their previous exacerbation history.  
A number of characteristics were statistically significantly different between groups at 
baseline. Reported p-values in table 1 should be interpreted with caution in view of the 
multiple comparisons performed.  
  
Consistency of the “frequent exacerbator phenotype” over time 
In the full analysis set, we examined the association between prior exacerbations and future 
exacerbation events. Compared to patients with 0 exacerbations at baseline, the IRR for future 
exacerbations was 1.73 (95%CI 1.47-2.02, p<0.0001) for 1 exacerbation per year, 3.14 (95%CI 
2.70-3.66, p<0.0001) for 2 exacerbations and 5.97 (95%CI 5.27-6.78, p<0.0001) for patients 
with >3 exacerbations per year, indicating that increasing exacerbations at baseline were 
associated with higher rates of exacerbation during follow-up.  
We next examined the ability of prior exacerbations to predict exacerbations in the following 
year (year 1 of follow-up). A history of 3 or more exacerbations in the previous year predicted 
3 or more exacerbations in the following year with a sensitivity 79.9% (95% CI 76.5-83.0%), 
specificity 75.8% (95% CI 73.9-77.7%), negative predictive value 92.3% (95% CI 90.8-93.5%), 
positive predictive value 51.1% (95% CI 47.9-54.3%), positive likelihood ratio 3.31 (95% CI 3.03-
3.61) and negative likelihood ratio 0.26 (95% CI 0.23-0.31). The area under the ROC curve for 
prior exacerbations to predict 3 or more exacerbations in the following year was 0.83 (95% 
0.81-0.85, p<0.0001). 
Equivalent data for a history of >2 exacerbations per year to identify patients having >2 
exacerbations in year 1 were the following: sensitivity 82.6% (95% CI 80.2-84.6%), specificity 
68.1% (95% CI 65.5-70.6%), positive predictive value 70.3% (95% CI 67.9-72.7%), negative 
predictive value 81.0% (95% CI 78.5-83.2%), positive likelihood ratio 2.59 95% CI 2.38-2.81, 
negative likelihood ratio 0.26 95% CI 22.6-29.0). The area under the ROC curve was 0.76 (95% 
CI 0.74-0.78, p<0.0001). These data suggest a high degree of agreement between baseline and 
first year exacerbation frequency.  
1236 patients had complete data for 4 years of exacerbation recording, including the 
frequency of exacerbations in the year prior to the study and for 3 years prospectively. 
Excluded patients were those who died during follow-up and any patient lost to follow-up. 
Patients with complete follow-up data therefore tended to be milder, with fewer co-
morbidities (supplementary table E1 and supplementary table E2 shows the proportion of 
patients lost to follow-up in each group). 
Using this cohort, figure 2 demonstrates the repeatability of exacerbation frequency over time. 
It demonstrates a clear relationship between prior exacerbation history and future risk even 
up to year 3. The proportional of patients that had 3 or more exacerbations at baseline and 
had 3 or more exacerbations in each year of the study was 24.0% of those with 3 or more 
events at baseline and 6.7% overall. The proportional of patients that experienced no 
exacerbations through all 4 years of exacerbation recording was 23.1% of those with 0 events 
at baseline and 8.2% of patients overall.  
To understand variation in exacerbation frequency, we used multivariable logistic regression to 
examine factors associated with a change in exacerbation status. Patients with <3 
exacerbations a year at baseline were more likely to change to have 3 or more exacerbations 
at follow-up if they were younger (per year as continuous variable) OR 0.98 (95% CI 0.97-0.99, 
p=0.002), had prior hospital admissions OR 2.45 (95% CI 1.40-4.26, p=0.002), H. influenzae 
infection OR 2.13, (95% CI 1.37-3.32, p=0.001), Enterobacteriaceae infection OR 2.97 (95% CI 
1.59-5.54, p=0.001), P. aeruginosa infection OR 2.17 (95% CI 1.12-4.21, p=0.02), a history of 
asthma OR 2.51 (95% CI 1.40-4.50, p=0.002) and lower FEV1 % predicted (as a continuous 
variable) OR 0.99 (95% CI 0.98-0.99, p=0.02). Predictors of a change from frequent to 
infrequent exacerbator status are shown in table E3 online.  
 
Independent risk factors for future exacerbations 
Based on the observation that prior exacerbations predict future events, we conducted a 
multivariable analysis to determine the independent contribution of different variables to 
future exacerbation risk. The strongest predictor of future exacerbations was a past history of 
exacerbations. The IRRs (95% CI) were 1.81 (1.54-2.12) for one exacerbation per year, 3.07 
(2.62-3.60) for 2 per year and 5.18 (4.51-5.95) for >3 per year (all p<0.0001 compared to 0 
exacerbations per year). The univariate and multivariate relationship between other risk 
factors and exacerbation frequency are listed in table 2. Sensitivity analyses adjusting for 
additional findings were consistent with this primary analysis and are shown in Table E4 online.  
The clear relationship between prior and future exacerbations remained significant in 
subgroups with mild, moderate and severe bronchiectasis. (table E4). Patients with a history of 
severe exacerbations were at higher risk of all exacerbations during follow-up, IRR 1.43 95% CI 
1.26-1.63,p<0.0001. Considering a history of severe and non-severe exacerbations separately 
made no difference to the overall conclusions (table E4 online).  
 
Impact of exacerbation history of morbidity and mortality 
Patients with frequent exacerbations at baseline had worse health status as measured by the 
SGRQ (figure 3). Differences between all groups were greater than the 4 point minimum 
clinically important difference except for the difference between patients with 0 and 1 
exacerbation per year at baseline. The scores were 32.5 (18.1-48.8) for patients with 0 
exacerbations, and then 35.9 (22.9-55.3), 44.0 (29.8-87.4) and 59.0 (37.7-74.9) for those with 
1, 2 and 3 or more exacerbations per year at baseline respectively, p<0.0001.  Patient QoL was 
worse in frequent exacerbators across all domains of the SGRQ (p<0.0001) and this is shown in 
figure E1 online. 
In a multivariable linear regression model, after adjustment for multiple confounders as listed 
in table 2, each additional exacerbation per year was associated with an independent 3.7-point 
increase in SGRQ total score (95% CI 2.58-4.87,p<0.0001). Separating hospitalized and non-
hospitalized exacerbations, the equivalent data were a 1.4 point increase for each individual 
outpatient exacerbation (95% CI 0.57-2.07,p=0.001) and a 9.8 point increase in those with a 
history of hospitalized exacerbations (95% CI 6.28-13.3,p<0.0001).  
The number of hospital admissions was also greater for those with >3 exacerbations in the 
previous year (40% of patients were hospitalized during follow-up) compared with those with 
2 (20.3%), 1 (11.3%) or 0 (11.1%) exacerbations at baseline, (p<0.0001 across groups), figure 4.  
Mortality was increased in patients with 3 or more exacerbations per year (figure 4).  
In a Cox proportional hazard regression adjusting for relevant confounding variables, 
compared to patients with 0 exacerbations at baseline, the hazard ratios (HR) for mortality 
were 0.92 (95% CI 0.57-1.48),p=0.7 for patients with 1 exacerbation, 1.60 (95% CI 1.06-
2.42,p=0.03) for patients with 2 exacerbations and HR 1.86 (95% CI 1.30-2.66, p=0.001) for 
patients with >3 exacerbations per year. Therefore patients with 2 or more exacerbations per 
year at baseline have an independent increase in mortality risk.  
Examining hospitalized and non-hospitalized exacerbations separately, the unadjusted and 
adjusted Hazard ratios were 3.24 95% CI 2.56-4.09,p<0.0001 and 1.97 95% CI 1.51-
2.57,p<0.0001 respectively for hospitalized exacerbations. For outpatient exacerbations only, 
the hazard ratios were consistent with the primary analysis with HR 0.83 95% CI 0.53-
1.31,p=0.4 for 1 exacerbation, 1.45 95% CI 0.98-2.16,p=0.06 for 2 exacerbations and HR 1.53 
95% CI 1.04-2.25,p=0.03 for 3 or more exacerbations.  
 
Sensitivity analysis- consistency of exacerbation frequency by centre and the impact of long-
term antibiotic treatment 
We finally investigated whether the consistency of the frequent exacerbator phenotype was a 
universal finding across European centres, and whether it was impacted by prior or newly 
initiated prophylactic antibiotic therapy. The results are shown in table 3. The precision of 
estimates varied across centres due to sample size, but the models indicated increasing future 
risk of exacerbations with increasing prior exacerbations in all countries. The AUC values 
ranged from 0.73-0.93 but all showed good to excellent discrimination of prior exacerbations 
for future exacerbations.  
Patients receiving prior antibiotic therapy had a higher frequency of exacerbations at baseline 
and during follow-up (mean 3.5 (standard deviation (SD) 2.5) per year at baseline, and 2.3 (SD 
1.9) during follow-up) as reflected in the higher rate ratio’s for future exacerbations in table 2, 
compared to patients not receiving prophylactic antibiotics at baseline 1.9 (SD 2.2) and follow-
up, 1.6 (SD 1.6). These data also show the trend for exacerbation frequency to reduce over 
time.  
We conducted a further sensitivity analysis examining the exacerbation frequency in 203 
patients who newly commenced prophylactic antibiotic therapy during follow-up, which are 
known to impact on future risk of exacerbation in clinical trials.(1,8) Data on patients newly 
commencing prophylactic antibiotic treatment was only available in 5 cohorts (Dundee, 
Newcastle, Edinburgh, Haifa and Leuven). These patients had a mean exacerbation rate of 4.1 
(SD 3.1) prior to therapy, reducing to 2.0 (SD 1.9) following therapy. Table 3 shows that despite 
this apparent response in terms of reduction in exacerbations, patients with a higher 
exacerbation frequency at baseline still had a higher rate of exacerbations during follow-up.  
Finally, since the frequent exacerbator phenotype has already been described in COPD, we 
conducted a sensitivity analysis excluding patients with co-existing COPD. These results are 
shown in table 3, and identified very similar estimates to the overall analysis.  
 
Discussion 
The objective of this study was to establish if the “frequent exacerbator” was a valid and 
clinically important phenotype in bronchiectasis.(19) Recognition of a frequent exacerbator 
phenotype in COPD linked to poorer health status, lung function decline and mortality has had 
a major impact on clinical care and clinical trial design.(20-24)  
In order to qualify as a phenotype, the characteristic or group of characteristics being studies 
should be measurable, consistent over time and be linked to clinically relevant outcomes.(13) 
Our results suggest that the frequent exacerbator phenotype meets these criteria, as 
exacerbation frequency showed relative stability over time, particularly in those with 3 or 
more exacerbations per year at baseline. Exacerbations were associated with an increased risk 
of death, an independent increase in the SGRQ, suggesting an independent contribution to 
impaired health status and were also linked to hospital admissions during follow-up.  
Our findings are clinically important because exacerbation reduction is one of the key goals of 
bronchiectasis management.(4-6) Our data suggests that without intervention, patients with 
frequent exacerbations are likely to continue to exacerbate frequently and that this will have 
negative consequences for QoL, healthcare utilization and mortality. This strengthens the 
arguments in favour of the use of therapies that have been shown to reduce exacerbations 
including macrolides, inhaled antibiotics, mucoactive therapies and pulmonary 
rehabilitation.(25-27) Data from the European and United States bronchiectasis registries 
suggest that despite a high burden of exacerbations, use of such therapies is low.(28-30) In the 
present cohort, 37% of patients had >3 exacerbations per year but only 1/3 were receiving 
prophylactic antibiotic therapies. It is acknowledged that the evidence base for most of these 
interventions remains weak. Our data also indicates the need for high quality randomized trials 
to prove conclusively that such therapies can reduce exacerbations.(25-27).  
Existing published data support the importance of exacerbations as an end-point in 
bronchiectasis. They are a major contributor to healthcare costs, and severe exacerbations 
have been linked to accelerated lung function decline.(31) Exacerbations form part of the 
multidimensional BSI which has been validated internationally as a predictor of outcome in 
bronchiectasis patients.(7) Several recent comparisons between the BSI and the similar FACED 
score found that FACED did not accurately predict future risk of exacerbations suggesting that 
it was not a valid predictor of severity of disease.(16,32) The major difference between the 
scores is that BSI incorporates history of exacerbations which are not included in 
FACED.(16,32) Modification of the FACED to include a past history of exacerbations has been 
shown to improve its prediction of exacerbations.(33) Our analysis explains why, since 
overwhelmingly the strongest predictor of future exacerbations is a prior history of 
exacerbations. Our data suggests that exacerbation history alone, without incorporating other 
variables, is sensitive and specific for predicting future events and so clinicians can use prior 
history for clinical decision making with a high degree of confidence. 
Our study was not designed to demonstrate why patients exacerbate and so our study does 
not imply that all patients with >3 exacerbations per year are the same. Most exacerbations of 
bronchiectasis are thought to be caused by bacterial infection, but there is also evidence that 
exacerbations are associated with viral infections(34), while other identified risk factors for 
exacerbations include elevated sputum neutrophil elastase activity(35), genetic 
polymorphisms such as FUT2(36) and mannose binding lectin(37), and multiple co-
morbidities.(17) Within the frequent exacerbator “phenotype” there may be multiple 
endotypes, biological subgroups with different patterns of bacteriological, inflammatory or 
genetic susceptibility to exacerbation.(38,39) Future studies should aim to examine and better 
defined these endotypes now that the clinical phenotype has been clearly established.(39) 
Our study has limitations. Exacerbations are poorly defined clinical entities in bronchiectasis 
and our study was conducted prior to the standardization of the definition of exacerbations by 
an EMBARC/Bronchiectasis research registry task force.(2) Hence, variations in antibiotic use in 
different countries may impact on the frequency of reported events. Our definition of severe 
exacerbations requires admission to hospital and may be affected by the availability of home 
intravenous antibiotic treatments in some countries.(40) Mild exacerbations not receiving 
antibiotic therapy but requiring an increase in the use of interventions like chest physiotherapy 
or inhaled therapies are not yet a widely accepted concept in bronchiectasis but have been 
shown to be important to clinical outcomes in COPD.(41,42) Future studies should attempt to 
address whether such events are important in bronchiectasis.   
For clinical trials, our data suggest that a history of exacerbations can be used to reliably 
identify a cohort of patients with future exacerbations to power trials where the primary 
outcome is the frequency of exacerbations. Recent trials recruiting patients with a history of 
>2 exacerbations per year have observed a relatively low rate of exacerbations during follow-
up. There are many possible reasons for this, including the tendency for milder patients to 
agree to enrolment in clinical trials and differences in the methods used to collect prior 
exacerbation history and follow-up exacerbation frequency.(43) Our data suggested that a 
history of >3 exacerbations had an optimal sensitivity and specificity for predicting future 
events and future trials may wish to consider using this as their inclusion criteria. 
In conclusion, frequently exacerbating patients with bronchiectasis represent a distinct clinical 
phenotype with different patient characteristics, a high risk of hospital admissions, poor QoL 
and a higher risk of death during follow-up. This study emphasizes the importance of 
prioritizing exacerbation reduction in the management of bronchiectasis. 
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Figure legends 
Figure 1. Patient groups and endpoints used in the analysis 
 
Figure 2. Exacerbation frequency during follow-up and the association with exacerbations in 
the previous year.  
 
Figure 3. St Georges Respiratory Questionnaire scores (SGRQ) according to baseline 
exacerbation frequency. (p<0.0001 by Kruskal-Wallis test).  
 
Figure 4. Annual survival and follow-up hospitalization rates in groups based on baseline 
exacerbations. 
  
Variables 
 
Full cohort 
0 exacerbations per 
year 
1 exacerbation per 
year 
2 exacerbation per 
year 
>3 exacerbation per 
year 
P-value 
(comparison 
across all 
groups) 
n. 2596 657 452 497 966 n/a 
Demographics        
     Median (IQR) age, 
years 
67 (57-74) 68 (58-75) 
67 (58-75) 66 (55-75) 66 (57-74) 
0.3 
          Age >65 years, n (%) 1395 (53.7%) 368 (56.0%) 251 (55.5%) 258 (51.9%) 505 (52.3%) 0.3 
          Age >75 years, n (%) 572 (22.0%) 164 (25.0%) 110 (24.3%) 107 (21.5%) 187 (19.4%) 0.03 
     Male, n (%) 1010 (38.9%) 244 (37.1%) 178 (39.4%) 181 (36.4%) 399 (41.3%) 0.2 
     Median (IQR) BMI  24.8 (21.8-28.1) 25 (22.0-27.9) 25 (21.9-28.1) 24.5 (21.5-27.5) 25 (21.5-28.6) 0.7 
     Either smokers or 
former smokers, n (%) 
990 (38.1%) 219 (33.3%) 
167 (37.0%) 188 (37.8%) 402 (41.6%) 
0.009 
Comorbidity       
     Ischaemic heart 
disease, n (%) 
453 (17.5%) 141 (21.5%) 
80 (17.7%) 74 (14.9%) 155 (16.1%) 
0.01 
     Stroke, n (%) 152 (5.9%) 57 (8.7%) 22 (4.9%) 20 (4.0%) 51 (5.3%) 0.003 
     Diabetes, n (%) 260 (10.0%) 85 (12.9%) 36 (8.0%) 35 (7.0%) 100 (10.4%) 0.004 
     Liver disease, n (%) 41 (1.6%) 7 (1.1%) 5 (1.1%) 6 (1.2%) 21 (2.2%) 0.2 
     Chronic renal failure, n 
(%) 
154 (5.9%) 36 (5.5%) 
24 (5.3%) 23 (4.6%) 70 (7.2%) 
0.2 
     COPD, n (%)  431 (16.6%) 60 (9.1%) 63 (13.9%) 84 (16.9%) 215 (22.2%) <0.0001 
     Asthma, n (%) 226 (8.7%) 37 (5.6%) 36 (8.0%) 53 (10.7%) 96 (9.9%) 0.006 
     Connective tissue 
disease, n (%) 
 210 (8.1%) 48 (7.3%) 
29 (6.4%) 44 (8.9%) 89 (9.2%) 
0.2 
     Neurological disease, n 
(%) 
68 (2.6%) 19 (2.9%) 
7 (1.5%) 12 (2.4%) 30 (3.1%) 
0.4 
     Osteoporosis, n (%) 192 (7.4%) 64 (9.7%) 29 (6.4%) 40 (8.0%) 57 (5.9%) 0.02 
     GERD, n (%) 394 (15.2%) 84 (12.8%) 58 (12.8%) 86 (17.3%) 162 (16.8%) 0.04 
    Haematological 
malignancy, n (%) 
33 (1.3%) 5 (0.8%) 
2 (0.4%) 10 (2.0%) 16 (1.7%) 
0.07 
     Solid tumor, n (%)  164 (6.3%) 24 (3.7%) 22 (4.9%) 32 (6.4%) 68 (7.0%) 0.02 
Disease severity       
     Median (IQR) BSI 
score,  
6 (4-10) 5 (3-7) 
5 (3-7) 5 (3-8) 11 (7-14) 
<0.0001 
     BSI score Risk Class, n 
(%) 
Mild 753 (29.0%) 277 (42.2%) 190 (42.0%) 186 (37.4%) 91 (9.4%)  
Moderate 926 (35.7%) 290 (44.1%) 180 (39.8%) 196 (39.4%) 250 (25.9%)  
Severe 917 (35.3%) 90 (13.7%) 82 (18.1%) 115 (23.1%) 625 (64.7%) <0.0001 
Radiological status       
     Median (IQR) Reiff 
score 
4 (2-6) 3 (2-6) 
3 (2-5) 3 (2-5) 4 (2-6) 
<0.0001 
Table 1. Patient characteristics according to previous exacerbation history. Abbreviations: 
BMI= body mass index, BSI= bronchiectasis severity index, COPD= chronic obstructive 
pulmonary disease, FEV1= forced expiratory volume in 1 second, GERD= gastrooesophageal 
reflux disease, IQR= interquartile range, MRC= medical research council, n/a= not applicable. 
 
 
 
 
 
 
Clinical status   
     MRC dyspnoea scale, 
median (IQR) 
2 (1-3) 2 (1-3) 
2 (1-3) 2 (1-3) 3 (2-4) 
<0.0001 
     Median (IQR) 
exacerbations in the 
previous year 
2 (0-3) 0 (0-0) 
1 (1-1) 2 (2-2) 4 (3-5) 
<0.0001 
    a t least one 
hospitalization in the 
previous year, n (%) 
672 (25.9%) 0 (0%) 
27 (6.0%) 95 (19.1%) 550 (56.9%) 
<0.0001 
Functional Status       
     Median (IQR) FEV1 % 
predicted 
73.8% (54.0-92.1) 80.8% (62.0-95.0) 
79.2% (61.0-95.3) 75.7% (56.3-93.9) 65.0% (46-85) 
<0.0001 
     FEV1 <35% predicted, 
n (%) 
181 (7.0%) 20 (3.0%) 
20 (4.4%) 22 (4.4%) 118  (12.2%) 
<0.0001 
     FEV1 <50% predicted, 
n (%) 
517 (19.9%) 79 (12.0%) 
75 (16.7%) 86 (17.3%) 274 (28.4%) 
<0.0001 
Microbiology       
     Chronic infection with 
at least one pathogen, n 
(%) 
1300 (50.7%)  244 (37.1%) 
192 (42.5%) 244 (49.1%) 618 (64.0%) 
<0.0001 
     P. aeruginosa, n (%) 389 (15.0%) 36 (5.5%) 26 (5.8%) 49 (9.9%) 277 (28.7%) <0.0001 
     H. influenzae, n (%) 569 (21.9%) 131 (19.9%) 93 (20.6%) 107 (21.5%) 237 (24.5%) 0.1 
     S. aureus, n (%) 156 (6.0%) 30 (4.6%) 21 (4.6%) 35 (7.0%) 70 (7.2%) 0.06 
     M. catarrhalis, n (%) 154 (5.9%) 31 (4.7%) 32 (7.1%) 31 (6.2%) 59 (6.1%) 0.4 
     Enterobacteriaceae, n 
(%) 
158 (6.1%) 23 (3.5%) 
23 (5.1%) 37 (7.4%) 75 (7.8%) 
0.002 
long-term antibiotic 
Treatment  
  
   
 
     Oral antibiotic 
treatment (incl. 
macrolides), n (%) 
503 (19.4%) 51 (7.8%) 
50 (11.1%) 79 (15.9%) 320 (33.1%) 
<0.0001 
     Inhaled antibiotic 
treatment, n (%) 
166 (6.4%) 9 (1.4%) 
7 (1.5%) 17 (3.4%) 132 (13.7%) 
<0.0001 
  Unadjusted Adjusted 
 IRR 95% CI p-value IRR 95% CI p-value 
0 Exacerbations 
1 Exacerbation 
2 Exacerbation  
3 Exacerbations 
Age (per 10 years) 
Gender (Male) 
MRC dyspnoea score 
FEV1 % predicted (per 10%) 
Reiff Score 
Smoking history 
Haemophilus influenzae 
Moraxella catarrhalis 
Staphylococcus aureus 
Enterobacteriaceae 
Pseudomonas aeruginosa 
Asthma 
COPD 
Idiopathic 
1.0 (reference) 
1.73 
3.14 
5.97 
1.00 
1.11 
1.24 
0.88 
1.04 
1.22 
1.07  
0.94 
1.19 
1.30 
1.94 
1.22 
1.89 
0.72 
 
1.47-2.02 
2.70-3.66 
5.27-6.78 
0.96-1.03 
1.00-1.23 
1.19-1.29 
0.87-0.90 
1.03-1.06 
1.10-1.35 
0.96-1.20 
0.78-1.14 
0.97-1.45 
1.08-1.57 
1.69-2.23 
1.03-1.44 
1.66-2.16 
0.65-0.79 
 
<0.0001 
<0.0001 
<0.0001 
0.8 
0.04 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.2 
0.5 
0.1 
0.006 
<0.0001 
0.02 
<0.0001 
<0.0001 
1.0 (reference) 
1.81 
3.07  
5.18 
0.96  
0.95 
1.02 
0.96 
1.02  
0.95 
1.13  
0.94 
1.08  
0.99 
1.20 
1.16 
1.43 
0.92 
 
1.54-2.12 
2.62-3.60 
4.51-5.95 
0.95-1.03 
0.86-1.06 
0.97-1.07 
0.94-0.98 
1.00-1.03 
0.85-1.06 
1.01-1.28 
0.77-1.15 
0.88-1.32 
0.82-1.20 
1.04-1.40 
0.98-1.38 
1.22-1.67 
0.83-1.02 
 
<0.0001 
<0.0001 
<0.0001 
0.6 
0.4 
0.4 
0.001 
0.05 
0.3 
0.04 
0.5 
0.5 
0.9 
0.01 
0.09 
<0.0001 
0.1 
Table 2. Adjusted and unadjusted incident rate ratios for exacerbation frequency during 
follow-up. Abbreviations: COPD= chronic obstructive pulmonary disease, FEV1= forced 
expiratory volume in 1 second, MRC= medical research council.  
 
  
  
 
Table 3. Sensitivity analysis of different countries and patient subgroups demonstrating the 
consistency of the frequent exacerbator phenotype over time.  
Subgroup                Incident rate ratio’s from the Poisson model            Area under the curve 
 1 
exacerbations 
2               
exacerbations         
3 or more 
exacerbations 
2 or more 
exacerbations 
3 or more 
exacerbations 
Country 
Belgium 
Greece 
Ireland 
Israel 
Italy 
Serbia 
Spain 
UK 
 
2.92 (1.47-5.82) 
0.71 (0.09-5.86) 
0.94 (0.07-12.0) 
5.63 (0.62-51.4) 
1.58 (1.08-2.33) 
6.00 (2.17-16.4) 
2.72 (1.78-4.15) 
1.39 (1.14-1.69) 
 
4.72 (2.36-9.44) 
1.52 (0.20-11.5) 
2.15 (0.19-24.9) 
9.47 (1.09-82.1) 
2.26 (1.56-3.29) 
11.0 (4.40-27.5) 
5.67 (3.68-8.73) 
2.60 (2.12-3.19) 
 
6.24 (3.32-11.7) 
3.57 (0.50-25.6) 
4.16 (0.37-46.2) 
13.1 (1.60-106) 
3.66 (2.65-5.07) 
20.9 (8.15-53.5)  
31.6 (22.3-45.0) 
5.49 (4.66-6.47) 
 
0.78 (0.71-0.84) 
0.77 (0.68-0.87) 
0.83 (0.78-0.88) 
0.73 (0.62-0.83) 
0.80 (0.76-0.85) 
0.91 (0.83-0.99) 
0.89 (0.87-0.91) 
0.80 (0.78-0.83) 
 
0.83 (0.76-0.89) 
0.85 (0.76-0.94) 
0.84 (0.78-0.90) 
0.79 (0.70-0.89) 
0.81 (0.76-0.87) 
0.93 (0.80-1.00) 
0.88 (0.86-0.90) 
0.85 (0.83-0.88) 
Prophylactic antibiotic 
use at baseline 
No prophylactic antibiotic 
use at baseline 
Commenced prophylactic 
antibiotics during the 
study 
Excluding COPD patients 
3.27 (1.67-6.41) 
 
2.00 (1.64-2.45) 
 
4.57 (1.35-15.5) 
 
 
2.14 (1.74-2.62) 
5.81 (3.1-10.7) 
 
2.93 (2.44-3.52) 
 
6.83 (2.12-22.1) 
 
 
3.12 (2.59-3.76) 
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